At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 84 enrolled
Drug / intervention
Glecaprevir/Pibrentasvirdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection
In Brief
A Phase 3 clinical trial evaluating Glecaprevir/Pibrentasvir for Hepatitis C Virus (HCV). Completed, enrolled 84 participants across 25 sites in 9 countries.
Detailed Summary
A Phase 3b, open-label, multicenter study to evaluate the efficacy and safety of glecaprevir/pibrentasvir for an 8- or 12-week treatment duration in participants with chronic hepatitis C virus (HCV) genotype (GT) 5 or 6 infection, with or without compensated cirrhosis respectively.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C Virus (HCV)
CountriesAustralia, Belgium, Canada, France, New Zealand, Singapore, South Africa, United States, Vietnam
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartJan 2017
Primary CompletionJun 2018
Study CompletionAug 2018
TodayJul 2026
First PostedNov 17, 2016
Enrollment StartJan 25, 2017
Primary CompletionJun 6, 2018
Study CompletionAug 29, 2018
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 9.6 years ago
Interventions
Glecaprevir/Pibrentasvirdrug
Fixed-dose combination tablets taken orally once a day.